Eli Lilly and Co. (NYSE:LLY) is currently the best performer in the S&P 500 (SP500), after the pharmaceutical announced that ...

Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are ...

On the charts, LLY has been climbing since its August 8th 52-week low of $623.78, heading for its 10th gain in the last 12 ...

New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to ...

Eli Lilly & Co’s experimental obesity pill orforglipron helped patients lose 9.6% of their body weight in a late-stage trial, ...

In a study of more than 1,600 adults with type 2 diabetes, those who received the highest dose of orforglipron on average shed 10.5% of their weight.

Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral ...

Eli Lilly has announced to go for global approval by the end of 2015 after completing the successful trials. The once-daily ...

Eli Lilly stated that results from a late-stage trial of its pill variant of GLP-1 drugs met the requirements for global ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Drugmaker Eli Lilly says its daily oral GLP-1 pill may help people who have obesity and people with Type 2 diabetes lose ...